Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis

A Baidoshvili, R Nijmeijer, W K Lagrand, C E Hack, H W M Niessen

This report hypothesises an active role for the acute phase protein, C reactive protein (CRP), in local inflammatory reactions. This was studied in infarction sites from liver and kidney in a patient who died as a result of multiple complications after cholecystectomy. In this patient, a general acute phase protein reaction was induced, with an increase in plasma CRP. In infarction sites of kidney and liver, colocalisation of CRP and activated complement were found, whereas non-infarct sites were negative for CRP and complement. These results suggest that CRP directly participates in local inflammatory processes, possibly via complement activation, after binding of a suitable ligand.

The physiological role of the acute phase protein C reactive protein (CRP) is not fully understood. It has been suggested that circulating CRP only reflects the extent of the acute phase reaction in response to non-specific stimuli. In contrast, studies have shown CRP to be localised in inflamed tissues (synovium and brain), and in atherosclerotic vessels or inflamed myocardium. Furthermore, recently for the first time we have found the formation of CRP-complement complexes in infarcted myocardial tissue (R Nijmeijer et al, 2001, unpublished results). We hypothesise that CRP plays an active role in local inflammatory reactions, and that in vitro CRP activates complement after binding to a suitable ligand.

"We hypothesise that C reactive protein plays an active role in local inflammatory reactions, and that in vitro C reactive protein activates complement after binding to a suitable ligand".

Our study on a patient who died of multiple complications after cholecystectomy, strengthens the specific role of CRP in local inflammation. This patient, a 46 year old woman, suffered from hypovolaemic shock after cholecystectomy, six weeks before death. Thereafter, she developed necrosis of the intestine (12 days before death) and multiple areas of infarction in kidneys and liver (six days before death). Furthermore, she developed sepsis (14 days before death), and the last measured CRP value was 149 mg/litre (normal value, 0–7) three days before death. To study the role of CRP, we performed immunohistochemical staining of the liver and kidney. Permission to use left over material (including fetal material) after the usual diagnostic process has been completed is part of the standard patient contract in our hospital.

In kidney and liver, CRP depositions were found in the infarcted tissue sites, with colocalisation of activated complement (fig 1A,B). In the liver, jeopardised hepatocytes and bile canaliculi stained for CRP. In the kidneys, CRP was found in jeopardised tubules and partly in glomeruli. In contrast, the non-infarcted sites did not stain for CRP. Moreover, liver and kidney tissues from an immature spontaneously aborted fetus, which can be regarded as non-ischaemic tissue controls, did not stain for CRP or complement either.

Furthermore, staining for CRP was not found in the liver or kidney tissue from an adult patient who died after cerebrovascular accident (which resulted in an increased CRP value in the blood). Therefore, depositions of CRP and complement in infarcted areas are not caused by non-specific binding after death. However, we cannot definitely exclude the possibility that other substances able to activate complement are also generated in the infarcted tissue.

In conclusion, in this patient with sepsis, resulting in an increase in plasma CRP, CRP and complement were localised specifically to infarcted tissue (kidney and liver), underlining the hypothesis that CRP directly participates in local inflammatory reactions.

Abbreviations: CRP, C reactive protein
inflammatory and necrotising processes, possibly via complement activation, after binding of a suitable ligand.

ACKNOWLEDGEMENTS
This study was financially supported by the Netherlands Heart Foundation, grant 93–119; 97–088. Dr Niessen is a recipient of the Dr E Dekker programme of the Netherlands Heart Foundation (D99025).

Authors’ affiliations
A Baidoshvili, R Nijmeijer, H W M Niessen, Department of Pathology, Vrije Universiteit Medical Center ICAR-VU, 1081 HV Amsterdam, The Netherlands
W K Lagrand, Department of Cardiology, Vrije Universiteit Medical Center
C E Hack, CLB, Sanguin Blood Supply Foundation, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands

Correspondence to: Dr HWM Niessen, Vrije Universiteit Medical Center, Department of Pathology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; jwm.niessen@vumc.nl

Accepted for publication 6 July 2001

REFERENCES